Drug Sponsors

Bayer to restructure

Wednesday, May 27, 2015 12:23 PM

The Bayer Group has released a financial update for 2014. The company had strengthened its life science businesses HealthCare and CropScience through acquisitions and decided to demerge the MaterialScience business. Dr. Marijn Dekkers, management board chairman, also listed four strategic priorities for Bayer’s successful further development.

More... »


AVEO Oncology relocates corporate headquarters in Massachusetts

Wednesday, May 27, 2015 12:22 PM

AVEO Oncology, a biopharmaceutical company developing targeted therapies through biomarker-driven insights, has relocated its corporate headquarters to Cambridge, Mass.

More... »


Mylan clarifies Perrigo offer

Wednesday, May 27, 2015 12:18 PM

Mylan was asked by the Irish Takeover Panel to issue the following clarification and retraction in accordance with the Irish Takeover Rules, relating to its firm intention to make an offer to acquire Perrigo. The clarification and retraction relates to certain forward-looking statements made by Mylan specifically during the pendency of the offer period concerning its long-stated target since 2012 of at least $6 in adjusted diluted earnings per share (EPS) by 2018, including recently in Mylan's first quarter earnings press release of May 5.

More... »

AbbVie completes acquisition of Pharmacyclics

Wednesday, May 27, 2015 12:17 PM

AbbVie has completed the acquisition of Pharmacyclics, enhancing AbbVie's scientific and commercial presence in oncology. Pharmacyclics primarily is aligned with the $24 billion global hematological oncology market with Imbruvica (ibrutinib), a BTK-inhibitor used to treat hematological cancers.

More... »

Fosun Pharma, HOPU Investments, CEL Healthcare Fund, WuXi PharmaTech to acquire Ambrx

Friday, May 22, 2015 01:50 PM

A consortium—consisting of entities affiliated with Shanghai Fosun Pharmaceutical Group, HOPU InvestmentsChina Everbright’s Healthcare Fund and WuXi PharmaTech—has signed a merger agreement to acquire Ambrx. The transaction is expected to close in the second quarter of 2015, subject to receipt of certain regulatory approvals and satisfaction of customary closing conditions.

More... »

Baxter, Baxalta highlight business strategies

Thursday, May 21, 2015 07:36 AM

In advance of the July 1 spin-off of Baxalta from Baxter International, executives from the companies have shared their vision, strategies and initiatives underway to drive product innovation and accelerated growth over the long-term. Each company has provided updates on its financial outlook, new product pipeline and growth prospects.

More... »

Foundry Medical Innovations to re-tool with merger and name change

Wednesday, May 20, 2015 03:19 PM

Foundry Medical Innovations, a Carslbad, Calif.-based comprehensive medical and diagnostic device development company, has merged with Zeis Consulting Group, a provider of IVD clinical research, and changed its name to Toolbox Medical Innovations to better leverage its strengths and serve its growing list of clients.

More... »

AstraZeneca to invest in new biologics manufacturing facility in Södertälje, Sweden

Wednesday, May 20, 2015 03:18 PM

AstraZeneca plans to invest approximately $285 million in a new high-tech facility for manufacturing of biological medicines in Södertälje, Sweden. The new plant will be focused on filling and packaging of protein therapeutics. The new facility will supply medicines for clinical trial programs of AZ and MedImmune, the company's global biologics R&D arm, from the end of 2018, and will deliver finished products for commercial use once fully operational by 2019.

More... »

Lannett to acquire Silarx Pharmaceuticals

Wednesday, May 20, 2015 03:17 PM

Lannett, a Philadelphia, Pa.-based developer and marketer of generic pharmaceutical products, has signed a definitive agreement to acquire privately held, New York-based Silarx Pharmaceuticals and a related real estate entity, a manufacturer and marketer of liquid generic pharmaceutical products. The transaction is expected to close in early June, subject to customary closing conditions. Strategic benefits of the acquisition include an FDA-approved manufacturing facility, research R&D experience and added diversity to Lannett’s portfolio of existing and pipeline products.  

More... »

Forum Pharmaceuticals relocates headquarters to Waltham, Massachusetts

Wednesday, May 20, 2015 03:15 PM

Forum Pharmaceuticals, a biopharmaceutical company focused on the development and delivery of innovative medicines to treat serious brain diseases, has relocated its corporate headquarters to a 112,500-square-foot, state-of-the-art facility located in Waltham, Mass. The move consolidates Forum’s operations into a single centralized location that houses corporate offices, clinical development and research laboratories. Previously, Forum conducted business from two locations in Watertown, Mass. and Brighton, Mass. The company also maintains a small European office in the Netherlands.

More... »

CenterWatch
CWWeekly

May 26

inVentiv Health aims to help sponsors prepare for new E.U. regulations on observational studies

ACRP partners with CRO Analytics to measure investigative sites' views of clinical trial quality

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

May

Job satisfaction mixed as workload increases
Salaries not keeping pace with rise in work, responsibilities

Gamification moving from early science to patient use
Pharma looking to use games for early diagnosis, recruitment, adherence

Already a subscriber?
Log in to your digital subscription.

Purchase the May issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

April

PSI, INC Research, Chiltern best with sites
Strategic outsourcing prioritizing, improving site relationships

Regulatory compliance an increasing burden on sites
Increased staff time, materials, storage eroding site operating profit

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs